

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/068933 A1

(51) International Patent Classification:
A61K 38/26 (2006.01) *A61P 1/00* (2006.01)

(21) International Application Number:
PCT/EP2023/077065

(22) International Filing Date:
29 September 2023 (29.09.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/377,868 30 September 2022 (30.09.2022) US

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Sydmarken 11, 2860 Soborg (DK).

(72) Inventors: **AGERSNAP, Mikkel Askjaer**; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Soborg (DK).
NIELSEN, Thor Schütt Svane; c/o Zealand Pharma A/S, Sydmarken 11, 2860 Soborg (DK).


(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: **GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND THEIR MEDICAL USES FOR THE TREATMENT OF SHORT BOWEL SYNDROME (SBS)**

FIG. 1



(57) Abstract: The present invention relates to glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), and their medical uses for the treatment of short bowel syndrome (SBS), and in particular to the treatments using glepaglutide that result in an early or significant reduction in the parenteral support (PS) required by patients undergoing GLP-2 therapy, even allowing patients to be weaned off the need for PS. In combination with a subpopulation of patients becoming SBS non-PS, the patients further reported an improvement in their Quality-of-Life (QoL).

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*